textabstractVerapamil hydrochloride, a calcium antagonist, has been recommended for the treatment of angina pectoris. The effectiveness of 3 × 120 mg verapamil was tested in 33 male patients with stable angina pectoris. The drug reduced the incidence of anginal episodes from 15 (1–98) to two (0–85) in four weeks (median, range); P < 0.01. The nitroglycerin consumption was similarly reduced. Exercise tolerance on a bicycle ergometer improved on the average by 10 W(P < 0.05). No side effects were observed. It is concluded that verapamil is an effective drug in the treatment of stable angina pectoris
Background: The pharmacokinetics, efficacy, and safety of calcium channel blockers have rarely been ...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
The aim of the study was to evaluate the effects of verapamil sustained release (SR) 240 mg, enalapr...
Verapamil hydrochloride, a calcium antagonist, has been recommended for the treatment of angina pect...
Verapamil hydrochloride, a calcium antagonist, has been recommended for the treatment of angina pect...
SUMMARY The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris...
SUMMARY The relative efficacy of two calcium antagonist drugs, verapamil, 120 mg three times a day a...
SUMMARY A therapeutic trial with verapamil, a calcium-antagonist drug, was performed in 12 patients ...
In a randomised, double-blind, crossover study of oral sustained-release verapamil 360 mg o.d. (&apo...
The efficacy of a once daily, sustained release formulation of verapamil (Verapamil SR, 360 mg) was ...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
SummaryStable angina is a form of coronary artery disease. Its potential to progress requires the mo...
Objective To study long-term treatment effects of meto-prolol or verapamil on combined cardiovascula...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
Background: The pharmacokinetics, efficacy, and safety of calcium channel blockers have rarely been ...
Background: The pharmacokinetics, efficacy, and safety of calcium channel blockers have rarely been ...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
The aim of the study was to evaluate the effects of verapamil sustained release (SR) 240 mg, enalapr...
Verapamil hydrochloride, a calcium antagonist, has been recommended for the treatment of angina pect...
Verapamil hydrochloride, a calcium antagonist, has been recommended for the treatment of angina pect...
SUMMARY The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris...
SUMMARY The relative efficacy of two calcium antagonist drugs, verapamil, 120 mg three times a day a...
SUMMARY A therapeutic trial with verapamil, a calcium-antagonist drug, was performed in 12 patients ...
In a randomised, double-blind, crossover study of oral sustained-release verapamil 360 mg o.d. (&apo...
The efficacy of a once daily, sustained release formulation of verapamil (Verapamil SR, 360 mg) was ...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
SummaryStable angina is a form of coronary artery disease. Its potential to progress requires the mo...
Objective To study long-term treatment effects of meto-prolol or verapamil on combined cardiovascula...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
Background: The pharmacokinetics, efficacy, and safety of calcium channel blockers have rarely been ...
Background: The pharmacokinetics, efficacy, and safety of calcium channel blockers have rarely been ...
A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effect...
The aim of the study was to evaluate the effects of verapamil sustained release (SR) 240 mg, enalapr...